Cogstate : Investor Update

Published: 2022-01-20 16:32:43 ET CGS.AX

For personal use only

ASX Announcement

21 January 2022

Investor Update

Cogstate (ASX.CGS) attaches an Investor Update.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error- prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, [email protected]

only

Investor Update

21 January 2022

use

Summary presentation of December quarter cashflow and business update.

This presentation should be read in conjunction with previous investor presentations

for a more detailed understanding of the business.

Detailed financial report for the half year ended 31 December 2021 is expected to be

released on Thursday 24 February 2022.

onal

onal use only

Disclaimer

This presentation has been prepared by Cogstate Limited ('Cogstate'). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act. This presentation may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not prove to be correct. None of Cogstate, its respective officers, employees, agents, advisers or any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward looking statements or any of the assumptions upon which they are based.

The information contained in this presentation does not take into account the investment objectives, financial situation or particular needs of any recipient and is not financial product advice. Before making an investment decision, recipients of this presentation should consider their own needs and situation and, if necessary, seek independent, professional advice.

To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Cogstate and its respective officers, employees, agents and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in this presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.

1H22 Financial Highlights (All figures in US$)

use only

Record clinical sales contracts executed

$54.5m

+141%

Alzheimer's disease represented 90% of

the value of contracts executed in 1H22

Record Group Revenue

Record contracted future revenue

$132.9m

+78%

Strong contracted future revenue pipeline

Net Cash balance / Cash Flow

onal

$23.1m

+67%

Clinical Trials revenue of $20.8m, up 66%

Healthcare revenue of $2.2m, up 93%

+631%

+33%

US$24.6m

An increase of $6.1m from a year ago

Clinical Trials Sales Contracts

onal use only US$ Millions

13.7

11.4

7.6

9.5

13.3

40.8

17.5

14.3

6.7

8.3

FY20

FY21

FY22

Quarter 1

Quarter 2

Quarter 3

Quarter 4

Record 1st Half

141% increase from the same period last year

90% of first half singings relate to Alzheimer's

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

CogState Ltd. published this content on 20 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2022 21:31:08 UTC.